Edwards Lifesciences Operating Margin 2010-2022 | EW

Current and historical operating margin for Edwards Lifesciences (EW) over the last 10 years. The current operating profit margin for Edwards Lifesciences as of December 31, 2022 is 28.81%.
Edwards Lifesciences Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-12-31 $5.38B $1.75B 32.50%
2022-09-30 $5.36B $1.68B 31.23%
2022-06-30 $5.36B $1.66B 31.06%
2022-03-31 $5.36B $1.75B 32.57%
2021-12-31 $5.23B $1.69B 32.30%
2021-09-30 $5.10B $1.67B 32.72%
2021-06-30 $4.93B $1.64B 33.19%
2021-03-31 $4.48B $0.92B 20.63%
2020-12-31 $4.39B $0.90B 20.45%
2020-09-30 $4.37B $0.86B 19.62%
2020-06-30 $4.32B $0.79B 18.35%
2020-03-31 $4.48B $1.23B 27.45%
2019-12-31 $4.35B $1.15B 26.38%
2019-09-30 $4.15B $0.83B 20.01%
2019-06-30 $3.97B $0.79B 19.82%
2019-03-31 $3.82B $0.77B 20.15%
2018-12-31 $3.72B $0.75B 20.11%
2018-09-30 $3.64B $1.06B 29.13%
2018-06-30 $3.55B $1.04B 29.24%
2018-03-31 $3.45B $1.04B 30.02%
2017-12-31 $3.44B $1.09B 31.74%
2017-09-30 $3.32B $0.96B 28.86%
2017-06-30 $3.23B $0.92B 28.58%
2017-03-31 $3.15B $0.89B 28.25%
2016-12-31 $2.96B $0.78B 26.43%
2016-09-30 $2.87B $0.79B 27.46%
2016-06-30 $2.74B $0.75B 27.27%
2016-03-31 $2.60B $0.68B 26.14%
2015-12-31 $2.49B $0.64B 25.78%
2015-09-30 $2.44B $0.62B 25.32%
2015-06-30 $2.43B $0.59B 24.34%
2015-03-31 $2.39B $0.56B 23.60%
2014-12-31 $2.32B $0.49B 21.23%
2014-09-30 $2.24B $0.47B 21.03%
2014-06-30 $2.13B $0.45B 21.00%
2014-03-31 $2.07B $0.46B 21.97%
2013-12-31 $2.05B $0.47B 23.12%
2013-09-30 $2.02B $0.49B 24.16%
2013-06-30 $1.97B $0.48B 24.19%
2013-03-31 $1.94B $0.45B 23.03%
2012-12-31 $1.90B $0.42B 22.12%
2012-09-30 $1.82B $0.36B 20.01%
2012-06-30 $1.78B $0.33B 18.44%
2012-03-31 $1.73B $0.31B 17.77%
2011-12-31 $1.68B $0.30B 17.87%
2011-09-30 $1.64B $0.29B 17.92%
2011-06-30 $1.58B $0.30B 19.09%
2011-03-31 $1.51B $0.30B 19.85%
2010-12-31 $1.45B $0.29B 19.70%
2010-09-30 $1.40B $0.27B 19.19%
2010-06-30 $1.38B $0.26B 18.78%
2010-03-31 $1.35B $0.25B 18.37%
2009-12-31 $1.32B $0.24B 18.07%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $50.772B $5.382B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Alcon (ALC) Switzerland $37.369B 32.17
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.950B 40.42
Glaukos (GKOS) United States $2.458B 0.00
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Nevro (NVRO) United States $1.410B 0.00
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00